Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.49 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.40 |
| ▸ | GRM1 | Q13255 | 4/20 | 0.39 |
| ▸ | GRM4 | Q14833 | 6/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.36 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.35 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.35 |
| ▸ | LDHA | P00338 | 1/20 | 0.35 |
| ▸ | LDHB | P07195 | 1/20 | 0.35 |
| ▸ | RPS6KA2 | Q15349 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14388704 | 0.99 | NAMPT (0.48) | NAMPTROCK2ROCK1GRM1GRM4 | |
| SCHEMBL5455808 | 0.99 | NAMPT (0.48) | NAMPTROCK2ROCK1GRM1GRM4 | |
| SCHEMBL13952739 | 0.89 | NAMPT (0.49) | NAMPTROCK2ROCK1GRM1GRM4 | |
| SCHEMBL5331486 | 0.88 | NAMPT (0.46) | NAMPTROCK2ROCK1GRM1GRM4 | |
| SCHEMBL30125632 | 0.88 | NAMPT (0.46) | NAMPTROCK2ROCK1GRM1GRM4 | |
| SCHEMBL12256159 | 0.87 | NAMPT (0.48) | NAMPTROCK2ROCK1GRM1GRM4 | |
| SCHEMBL6431430 | 0.87 | NAMPT (0.48) | NAMPTROCK2ROCK1GRM1GRM4 | |
| SCHEMBL14361885 | 0.87 | NAMPT (0.40) | NAMPTROCK2ROCK1GRM1GRM4 | |
| SCHEMBL12256129 | 0.86 | NAMPT (0.47) | NAMPTROCK2ROCK1GRM1GRM4 | |
| SCHEMBL5331221 | 0.85 | NAMPT (0.46) | NAMPTROCK2ROCK1GRM1GRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025122762-A1 | COMPOUNDS AND METHODS FOR TREATING SICKLE CELL DISEASE | Design Therapeutics, Inc. (US) | 2025-06-12 | — | — | WO | disclosed |
| US-20240360105-A1 | PROCESS FOR POLYAMIDE SYNTHESIS | Design Therapeutics, Inc. | 2024-10-31 | — | — | US | disclosed |
| EP-4384506-A1 | PROCESS FOR POLYAMIDE SYNTHESIS | Design Therapeutics, Inc. (US) | 2024-06-19 | — | — | EP | disclosed |
| WO-2023014793-A1 | PROCESS FOR POLYAMIDE SYNTHESIS | Design Therapeutics, Inc. (US) | 2023-02-09 | — | — | WO | disclosed |
| US-8524899-B2 | Oligopeptide containing fused 6-membered ring forming complexes with double stranded dna; complexes can be used for identification of specific dsDNA sequences, inhibiting gene transcription, therapeutic for inhibiting proliferation of undesired cells or modulation of expression of specific gene | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2013-09-03 | — | — | US | disclosed |
| US-8524899-B2 | Oligopeptide containing fused 6-membered ring forming complexes with double stranded dna; complexes can be used for identification of specific dsDNA sequences, inhibiting gene transcription, therapeutic for inhibiting proliferation of undesired cells or modulation of expression of specific gene | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2013-09-03 | — | — | US | disclosed |
| EP-1599474-B1 | Heterocyclic oligomeric compounds for DNA recognition | CALIFORNIA INST OF TECHN (US) | 2013-04-24 | — | — | EP | disclosed |
| US-8017599-B2 | Sequence selective pyrrole and imidazole polyamide metallocomplexes | UNIVERSITY OF WESTERN SYDNEY (AU) | 2011-09-13 | — | — | US | disclosed |
| US-20070265240-A1 | Sequence Selective Pyrrole and Imidazole Polyamide Metallocomplexes | UNIVERSITY OF WESTERN SYDNEY (AU) | 2007-11-15 | — | — | US | disclosed |
| US-20070265240-A1 | Sequence Selective Pyrrole and Imidazole Polyamide Metallocomplexes | UNIVERSITY OF WESTERN SYDNEY (AU) | 2007-11-15 | — | — | US | disclosed |
| WO-2007045096-A1 | OLIGOHETEROAROMATIC LUMINISCENT ASSEMBLIES AS HIGH-AFFINITY DNA SEQUENCE-DIRECTED LIGANDS | UNIVERSITY OF SASKATCHEWAN (CA) | 2007-04-26 | — | — | WO | disclosed |
| US-6924396-B2 | α-haloenamine reagents | PHARMACIA CORPORATION (US) | 2005-08-02 | — | — | US | disclosed |
| EP-1430028-A2 | AROMATIC AND HETEROAROMATIC ACID HALIDES FOR SYNTHESIZING POLYAMIDES | Pharmacia Corporation (US) | 2004-06-23 | — | — | EP | disclosed |
| EP-1421056-A1 | (ALPHA)-HALOENAMINE REAGENTS | Pharmacia Corporation (US) | 2004-05-26 | — | — | EP | disclosed |
| US-20040092770-A1 | Alpha-haloenamine reagents | PHARMACIA CORPORATION | 2004-05-13 | — | — | US | disclosed |
| US-6677487-B2 | COMBINING A TERTIARY AMIDE WITH A PENTAVALENT PHOSPHOROUS HALIDE IN A SOLVENT TO FORM AN ALPHA - HALOIMINIUM SALT AND CONVERTING THE ALPHA -HALOIMINIUM SALT TO THE ALPHA -HALOENAMINE WITH A BASE | PHARMACIA CORPORATION | 2004-01-13 | — | — | US | disclosed |
| US-20030105279-A1 | Aromatic and heteroaromatic acid halides for synthesizing polyamides | PHARMACIA CORPORATION | 2003-06-05 | — | — | US | disclosed |
| US-20030080320-A1 | Alpha- haloenamine reagents | PHARMACIA CORPORATION | 2003-05-01 | — | — | US | disclosed |
| WO-2003020684-A1 | (ALPHA)-HALOENAMINE REAGENTS | PHARMACIA CORPORATION (US) | 2003-03-13 | — | — | WO | disclosed |
| WO-2003018552-A2 | AROMATIC AND HETEROAROMATIC ACID HALIDES FOR SYNTHESIZING POLYAMIDES | PHARMACIA CORPORATION (US) | 2003-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360105-A1 | PROCESS FOR POLYAMIDE SYNTHESIS | POLI, POLR2A, POLR2B | NAMPT 1291/4885ROCK2 4504/4885ROCK1 4749/4885 |
| US-20030080320-A1 | Alpha- haloenamine reagents | HNMT, HDHD5, NISCH | NAMPT 1822/4885ROCK2 3116/4885ROCK1 2683/4885 |
| US-20040092770-A1 | Alpha-haloenamine reagents | HNMT, HDHD5, NISCH | NAMPT 1822/4885ROCK2 3116/4885ROCK1 2683/4885 |
| US-20070265240-A1 | Sequence Selective Pyrrole and Imidazole Polyamide Metallocomplexes | POLRMT, MPI, PPIF | NAMPT 495/4885ROCK2 3694/4885ROCK1 4269/4885 |
| US-20030105279-A1 | Aromatic and heteroaromatic acid halides for synthesizing polyamides | AAAS, HTT, HRH4 | NAMPT 3894/4885ROCK2 4635/4885ROCK1 4536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.